Mar 6, 2025
|
ASX:EIQ
|
23 min
Yesterday EIQ released a comprehensive update on all aspects of the business, five months after getting US FDA clearance for helping cardiologists detect a heart disease called aortic stenosis. With US FDA clearance in hand, EIQ has quickly started commercialisation - it’s hired an experienced US based CEO, secured a reimbursement code (important for how EIQ makes money), and integrated its tech in five US hospitals.